Report from the third Progressive MS Alliance Industry Forum meeting
On February 16-17, 2017, the Alliance held its third annual Industry Forum meeting in Washington D.C., USA. During the meeting, the Alliance facilitated a review of key areas across the MS research landscape, conducted ongoing discussions towards enabling the development of therapies for progressive MS, and worked towards identifying the future Alliance research strategy – building upon our progress.
Present at the meeting were Industry Forum members, Industry and Biotech representatives, Alliance managing members and the Scientific Steering Committee, FDA regulatory representatives and Alliance-funded Collaborative Network lead investigators. This meeting ensures all necessary stakeholders that change the world for people with progressive MS, come together, and with a focus on identifying the key opportunities and challenges that must be addressed.
Presentations, followed by provoking discussions, stimulated conversation and encouraged collaboration towards meeting the following objectives.
- Solidify and refine Industry Forum’s role, commitment and shared objectives within the work of the Alliance.
- Advance discussions and develop actions on the key focus areas of the Industry Forum – paths to enable therapeutic development; data sharing; and pathophysiology.
- Identify opportunities and synergies to strengthen the Collaborative Networks.
- Engage regulatory authorities and gather insight towards developing solutions for people living with progressive MS.
- Provide advice to the Alliance Scientific Steering Committee.
- Strong atmosphere of collaboration with a recognition that working together will lead to more effective and timely solutions.
- Clear synergies between the Scientific Steering Committee and Industry Representatives towards the future strategies of the Alliance.
- Strong engagement with FDA Regulatory Representatives with confirmation of their willingness to collaborate.
- Agreement that the MS community must continue to seek solutions to speed up clinical trial processes and de-risk development of therapies for progressive MS.
- The progressive MS landscape is changing, progress is being made and the community must acknowledge this evolution and shift priorities accordingly.
- There is a need for mechanisms that better share clinical data among the community.
Sign up to our e-newsletterfor updates from our growing global initiative to end progressive MS
Clicking submit confirms that you consent to MSIF sending you the Progressive MS Alliance newsletter
Please note, you must be aged 18 or older to subscribe to our newsletters.